Background
Methods
Ethics statement
Study design and patient management
Data collection
Outcome definition and ascertainment
Statistical analysis
Results
Clinical, demographic, socioeconomic and behavioral descriptions of study population
Characteristics | |||||
---|---|---|---|---|---|
Number of participants (% of total) | UATH (site %) | ADH (site %) | UBTH (site %) | p-value§
| |
Gender
| 0.31 | ||||
Female | 400 (63.7%) | 128 (59.8%) | 110 (67.1%) | 162 (64.8%) | |
Male | 228 (36.3%) | 86 (40.2%) | 54 (32.9%) | 88 (35.2%) | |
Age at HAART Initiation
(years)
| |||||
Median (Inter-quartile range) | 35 (30 – 41) | 34 (29 – 41) | 34 (29 – 38) | 36 (30 – 45) | 0.001 |
< 30 | 190 (30.3%) | 70 (32.7%) | 55 (33.5%) | 65 (26%) | |
31 to 40 | 271 (43.1%) | 89 (41.6%) | 84 (51.2%) | 98 (39.2%) | |
41 to 50 | 120 (19.1%) | 43 (20.1%) | 20 (12.2%) | 57 (22.8%) | |
>51 | 47 (7.5%) | 12 (5.6%) | 5 (3.1%) | 30 (12%) | |
Marital Status
| 0.001 | ||||
Single | 146 (23.2%) | 43 (20.1%) | 47 (28.7%) | 56 (22.4%) | |
Married / Cohabiting | 359 (57.2%) | 136 (63.6%) | 88 (53.7%) | 135 (54%) | |
Separated | 45 (7.2%) | 5 (2.3%) | 9 (5.5%) | 31 (12.4%) | |
Divorced / Widowed | 78 (12.4%) | 30 (14%) | 20 (12.2%) | 28 (11.2%) | |
Currently married
| 0.07 | ||||
Yes | 359 (57.2%) | 136 (63.6%) | 88 (53.7%) | 135 (54%) | |
No | 269 (42.8%) | 78 (36.4%) | 76 (46.3%) | 115 (46%) | |
Residential Distance
(in kilometers)
| 0.001 | ||||
Median (inter-quartile range) | 25 (10 – 80) | 46.5 (20 – 90) | 23 (15 – 30) | 10 (5 – 130) | |
< 50 | 402 (64%) | 109 (50.9%) | 133 (81.1%) | 160 (64%) | |
51 to100 | 80 (12.7%) | 54 (25.2%) | 16 (9.8%) | 10 (4%) | |
101 to 200 | 120 (19.1%) | 44 (20.6%) | 6 (3.7%) | 70 (28%) | |
>200 | 26 (4.1%) | 7 (3.3%) | 9 (5.5%) | 10 (4%) | |
HIV disclosure
| 0.34 | ||||
Yes | 595 (94.7%) | 204 (95.3%) | 158 (96.3%) | 233 (93.2%) | |
No | 33 (5.3%) | 10 (4.7%) | 6 (3.7%) | 17 (6.8%) | |
Tuberculosis History
| 0.001 | ||||
Yes | 90 (14.3%) | 18 (8.4%) | 37 (22.6%) | 35 (14%) | |
No | 538 (85.7%) | 196 (91.6%) | 127 (77.4%) | 215 (86%) | |
Baseline CD4 cell count
(n = 613)
| 0.001 | ||||
Median (inter-quartile range) | 142 (85 – 223) | 117 (72 – 175) | 187 (111 – 266) | 150 (88 – 241) | |
< 50 | 88 (14.4%) | 42 (19.8%) | 15 (9.3%) | 31 (13%) | |
50 and < 200 | 336 (54.8%) | 143 (67.5%) | 74 (45.7%) | 119 (49.8%) | |
200 and <350 | 155 (25.3%) | 19 (9%) | 54 (33.3%) | 82 (34.3%) | |
350 and < 500 | 24 (3.9%) | 4 (1.9%) | 16 (9.9%) | 4 (1.7%) | |
>=500 | 10 (1.6%) | 4 (1.9%) | 3 (1.9%) | 3 (1.3%) | |
Baseline Hemoglobin
(g/dl)
(n = 546)
| 0.001 | ||||
Median (inter-quartile range) | 10.9 (9.3 – 12.4) | 10.5 (8.8 – 11.9) | 12.1 (10.8 – 13.9) | 10.3 (8.9 – 11.6) | |
> =10 | 354 (64.9%) | 107 (60.1%) | 131 (84%) | 116 (54.7%) | |
>=8 and <10 (Grade 1 anemia) | 141 (25.8%) | 57 (32%) | 17 (10.9%) | 67 (31.6%) | |
>=7 and <8 (Grade 2 anemia) | 33 (6.0%) | 7 (3.9%) | 7 (4.5%) | 19 (9%) | |
>=6.5 and <7 (Grade 3 anemia) | 7 (1.3%) | 3 (1.7%) | 0 (0%) | 4 (1.9%) | |
< 6.5 (Grade 4 anemia) | 11 (2.0%) | 4 (2.3%) | 1 (0.6%) | 6 (2.8%) | |
Baseline anemia
(Hemoglobin < 10 g/dl)
(n = 546)
| |||||
Yes | 192 (35.2%) | 71 (39.9%) | 25 (16%) | 96 (45.3%) | |
No | 354 (64.8%) | 107 (60.1%) | 131 (84%) | 116 (54.7%) | |
Antiretroviral drug regimen at baseline
| 0.001 | ||||
ZDV / 3TC / NVP or EFV | 257 (40.9%) | 58 (27.1%) | 76 (46.3%) | 123 (49.2%) | |
D4T / 3TC / NVP or EFV | 50 (8.0%) | 15 (7%) | 10 (6.1%) | 25 (10%) | |
TDF / 3TC of FTC / NVP or EFV | 321 (51.1%) | 141 (65.9%) | 78 (47.6%) | 102 (40.8%) | |
Baseline Functionality
| 0.001 | ||||
Working (70-100%) | 170 (81.3%) | 71 (44.7%) | 238 (96.8%) | ||
Ambulatory (50-70%) | 479 (78%) | 38 (18.2%) | 78 (49.1%) | 7 (2.8%) | |
Bedridden (<50%) | 123 (20%) | 1 (%) | 10 (6.3%) | 1 (0.4%) | |
12 (2%) | |||||
Reason for ART eligibility
| |||||
CD4 cell count < 200 | 188 (90.4%) | 91 (56.5%) | 159 (67.1%) | 0.001 | |
CD4 cell count < 350 and WHO Stage 3 | 438 (72.2%) | 14 (6.7%) | 55 (34.2%) | 75 (31.7%) | |
WHO Stage 4 | 144 (23.8%) | 1 (0.5%) | 14 (8.7%) | 3 (1.3%) | |
Other (PMTCT plus, etc.) | 18 (3%) | 5 (2.4%) | 1 (0.6%) | 0 (0%) | |
6 (1%) | |||||
Drug adherence by pharmacy refill record calculated over 12 months
| 0.001 | ||||
>= 95% | 576 (91.7%) | 202 (94.4%) | 137 (83.5%) | 237 (94.8%) | |
< 95% | 52 (8.3%) | 12 (5.6%) | 27 (16.5%) | 13 (5.2%) | |
Drug adherence by self-report at 12 months
| 0.08 | ||||
>= 95% | 544 (86.6%) | 193 (90.2%) | 135 (82.3%) | 216 (86.4%) | |
< 95% | 84 (13.4%) | 21 (9.8%) | 29 (17.7%) | 34 (13.6%) | |
Virologic suppression
(<400 copies) (n = 591)
| 0.001 | ||||
Yes | 453 (76.7%) | 167 (78.4%) | 94 (71.2%) | 192 (78%) | |
No | 138 (23.3%) | 46 (21.6%) | 38 (28.8%) | 54 (22%) | |
Immunologic recovery
(CD4 cell change >=50)
(n = 596)
| 0.01 | ||||
Yes | 461 (77.4%) | 178 (84.4%) | 110 (74.3%) | 173 (73%) | |
No | 135 (22.6%) | 33 (15.6%) | 38 (25.7%) | 64 (27%) | |
Employment status
| 0.001 | ||||
Employed | 524 (83.4%) | 183 (85.5%) | 116 (70.7%) | 225 (90%) | |
Unemployed | 99 (15.8%) | 27 (12.6%) | 48 (29.3%) | 24 (9.6%) | |
Retired | 1 (0.2%) | 1 (0.5) | 0 (0%) | 0 (0%) | |
Student | 4 (0.6%) | 3 (1.4%) | 0 (0%) | 1 (0.4%) | |
Highest educational achievement
| 0.001 | ||||
No formal education | 301 (47.9%) | 92 (43%) | 80 (48.8%) | 129 (51.6%) | |
Primary education | 136 (21.7%) | 54 (25.2%) | 22 (13.4%) | 60 (24%) | |
Secondary education | 34 (5.4%) | 14 (6.5%) | 17 (10.4%) | 3 (1.2%) | |
Post-secondary / Tertiary / Advanced Education (M.Sc., Ph.D.) | 157(25%) | 54 (25.3%) | 45 (27.4%) | 58 (23.2%) | |
Socio-economic class
| 0.001 | ||||
Class 1 | 23 (3.7%) | 13 (6.1%) | 2 (1.2%) | 8 (3.2%) | |
Class 2 | 99 (15.6%) | 27 (12.6%) | 22 (13.4%) | 50 (20%) | |
Class 3 | 276 (44%) | 79 (36.9%) | 63 (38.4%) | 134 (53.6%) | |
Class 4 | 207 (33%) | 88 (41.1%) | 66 (40.3%) | 53 (21.2%) | |
Class 5 | 23 (3.7%) | 7 (3.3%) | 11 (6.7%) | 5 (2%) | |
Current smoker
| 0.65 | ||||
Yes | 11 (1.8%) | 5 (2.3%) | 3 (1.8%) | 3 (1.2%) | |
No | 617 (98.2%) | 209 (97.7%) | 161 (98.2%) | 247 (98.8%) | |
Current drug user
| 0.24 | ||||
Yes | 1 (0.2%) | 0 (0%) | 1 (0.6%) | 0 (0%) | |
No | 627 (99.8%) | 214 (100%) | 163 (99.4%) | 250 (100%) | |
Current alcohol user
| 0.001 | ||||
Yes | 53 (8.4%) | 2 (0.9%) | 29 (17.7%) | 22 (8.8% | |
No | 575 (91.6%) | 212 (99.1%) | 135 (82.3%) | 228 (91.2%) | |
Current herbal drug user
| 0.03 | ||||
Yes | 20 (3.2%) | 3 (1.4%) | 10 (6.1%) | 7 (2.8%) | |
No | 608 (96.8%) | 211 (98.6%) | 154 (93.9%) | 243 (7.2%) |
Characteristics | Lost-To-Follow-Up | Study participants | p-value§
|
---|---|---|---|
(n = 805) | (n = 628) | ||
Gender
| 0.99 | ||
Female | 513 (63.7%) | 400 (63.7%) | |
Male | 292 (36.3%) | 228 (36.3%) | |
Age at HAART Initiation
(years)
| 0.04 | ||
Median (Inter-quartile range) | 33 (28–40) | 35 (30–41) | |
< 30 | 304 (37.7%) | 190 (30.3%) | |
31 to 40 | 306 (38%) | 271 (43.1%) | |
41 to 50 | 139 (17.3%) | 120 (19.1%) | |
>50 | 56 (7%) | 47 (7.5%) | |
Marital Status
(n = 2398)
‡
| 0.15 | ||
Single | 184 (24.7%) | 146 (23.2%) | |
Married / Cohabiting | 449 (60.4%) | 359 (57.2%) | |
Separated | 40 (5.4%) | 45 (7.2%) | |
Divorced / Widowed | 71 (9.5%) | 78 (12.4%) | |
Currently married
(n = 2398)
| 0.23 | ||
Yes | 449 (60.3%) | 359 (57.2%) | |
No | 295 (39.7%) | 269 (42.8%) | |
Residential Distance
(in kilometers)
(n = 2295)
‡
| 0.001 | ||
Median (inter-quartile range) | 15 (10–75) | 25 (10–80) | |
< 50 | 486 (60.4%) | 402 (64%) | |
51 and < 100 | 134 (16.7%) | 80 (12.7%) | |
101 and <200 | 100 (12.4%) | 120 (19.1%) | |
>=200 | 13 (1.8%) | 26 (4.1%) | |
HIV disclosure
(n = 2082)
‡
| 0.28 | ||
Yes | 481 (93.2%) | 595 (94.7%) | |
No | 35 (6.8%) | 33 (5.3%) | |
Tuberculosis History
(n = 2025)
‡
| 0.76 | ||
Yes | 72 (13.7%) | 90 (14.3%) | |
No | 453 (86.3%) | 538 (85.7%) | |
Baseline CD4 count
(n = 2033)
‡
| 0.001 | ||
Median (inter-quartile range) | 119 (54–218) | 142 (85–223) | |
< 50 | 137 (22.6%) | 88 (14.4%) | |
>=50 and < 200 | 301 (49.7%) | 336 (54.8%) | |
>=200 and <350 | 99 (16.3%) | 155 (25.3%) | |
>=350 and < 500 | 29 (4.8%) | 24 (3.9%) | |
>=500 | 40 (6.6%) | 10 (1.6%) | |
Baseline Hemoglobin
(g/dl)
(n − 1606)
‡
| 0.001 | ||
Median (inter-quartile range) | 9.9 (8–11.5) | 10.9 (9.3-12.4) | |
> =10 | 228 (48.6%) | 354 (64.8%) | |
>=8 and <10 (Grade 1 anemia) | 127 (27.1%) | 141 (25.8%) | |
>=7 and <8 (Grade 2 anemia) | 42 (9%) | 33 (6%) | |
>=6.5 and <7 (Grade 3 anemia) | 14 (3%) | 7 (1.3%) | |
< 6.5 (Grade 4 anemia) | 58 (12.4%) | 11 (2%) | |
Baseline anemia
(Hemoglobin
< 10g/dl)
| 0.001 | ||
Yes | 241 (51.4%) | 192 (35.2%) | |
No | 228 (48.6%) | 354 (64.8%) | |
Antiretroviral drug regimen at baseline
| 0.001 | ||
ZDV / 3TC / NVP or EFV | 276 (34.3%) | 275 (40.9%) | |
D4T / 3TC / NVP or EFV | 193 (24%) | 50 (8%) | |
TDF / 3TC of FTC / NVP or EFV | 336 (41.7%) | 321 (51.1%) |
Immuno-virologic parameters at 12 months on ART
Predictors of virologic and immunologic outcomes at 12 months on ART
Characteristics | ||||||
---|---|---|---|---|---|---|
ALL | Virologic failure | Unadjusted | p-value | Adjusted | p-value | |
(n = 591) | (n = 138) | OR (95% CI) | OR (95% CI) | |||
Gender
| ||||||
Female | 374 | 87 (63%) | Ref | Ref | 0.33 | |
Male | 217 | 51 (37%) | 1.01 (0.68 – 1.5) | 0.95 | 1.40 (0.72-2.07) | |
Age at HAART Initiation
(years)
| ||||||
< 30 | 175 | 42 (30.4%) | 1.51 (0.98-2.3) | 0.06 | 1.79 (1.17-2.67) | 0.03 |
>30 | 416 | 96 (69.6%) | Ref | Ref | ||
Currently married
| ||||||
Yes | 339 | 79 (43%) | 0.99 (0.68-1.46) | 0.98 | ||
No | 252 | 59 (57%) | Ref | |||
Residential Distance
(in kilometers)
| ||||||
< 50 | 372 | 90 (65%) | Ref | Ref | ||
51 to100 | 80 | 10 (7%) | 0.45 (0.22-0.92) | 0.03 | 0.44 (0.22-0.84) | 0.04 |
>100 | 143 | 38 (28%) | 1.17 (0.73-1.87) | 0.49 | 1.37 (0.91-2.35) | 0.24 |
HIV disclosure
| ||||||
Yes | 559 | 132 (96%) | 0.75 (0.30-1.85) | 0.53 | ||
No | 32 | 6 (4%) | Ref | |||
Tuberculosis History
| ||||||
Yes | 84 | 26 (19%) | 1.58 (0.95-2.63) | 0.08 | 1.20 (0.72-2.28) | 0.46 |
No | 507 | 112 (81%) | Ref | Ref | ||
Baseline CD4 cell count
(n = 613)
| ||||||
< 50 | 85 | 24 (17%) | Ref | Ref | ||
50 and < 200 | 317 | 79 (57%) | 0.84 (0.49-1.44) | 0.54 | 0.82 (0.47-1.46) | 0.53 |
200 and <350 | 143 | 26 (19%) | 0.56 (0.30-1.07) | 0.08 | 0.54 (0.22-0.93) | 0.08 |
350 and < 500 | 22 | 5 (4%) | 0.75 (0.25-2.25) | 0.61 | 0.48 (0.17-2.53) | 0.24 |
>=500 | 24 | 4 (3%) | 0.51 (0.16-1.64) | 0.26 | 0.58 (0.19-2.6) | 0.38 |
Baseline anemia
Hemoglobin <
10 g/dl)
(n = 591)
| ||||||
Yes | 200 | 58 (42%) | 1.59 (1.07-2.35) | 0.02 | 1.71 (1.22-2.61) | 0.03 |
No | 391 | 84 (58%) | Ref | Ref | ||
Antiretroviral drug regimen at baseline
| ||||||
ZDV / 3TC / NVP or EFV | 247 | 56 (40.6%) | Ref | Ref | ||
D4T / 3TC / NVP or EFV | 48 | 14 (10.1%) | 1.32 (0.70-2.80) | 0.34 | 1.35 (0.64-2.95) | 0.45 |
TDF / 3TC of FTC / NVP or EFV | 296 | 68 (50.3%) | 0.94 (0.68-1.52) | 0.93 | 0.90 (0.65-1.66) | 0.79 |
Baseline Functionality
| ||||||
Working (70-100%) | 460 | 96 (71.1%) | Ref | Ref | ||
Ambulatory (50-70%) | 106 | 34 (25.2% ) | 0.32 (0.09-1.06) | 0.062 | 0.34 (0.12-1.18) | 0.09 |
Bedridden (<50%) | 11 | 5 (3.7%) | 0.57 (0.16-1.99) | 0.375 | 0.60 (0.14-1.87) | 0.39 |
Drug adherence by pharmacy refill record
| ||||||
>= 95% | 543 | 114 (80%) | Ref | Ref | ||
< 95% | 48 | 24 (20%) | 3.76 (2.06-6.87) | 0.001 | 3.82 (2.17-5.97) | 0.001 |
Employment status
| ||||||
Employed | 496 | 111 (80%) | Ref | Ref | ||
Unemployed | 90 | 26 (19%) | 1.41 (0.85-2.33) | 0.18 | 1. 37 (0.88-2.10) | 0.26 |
Retired | 1 | 0 (0%) | Omitted | Omitted | Omitted | |
Student | 4 | 1 (1%) | 1.16 (0.12-11.2) | 0.90 | 1.18 (0.15-10.6) | 0.94 |
Highest educational achievement
| ||||||
No formal education | 283 | 80 (58%) | Ref | Ref | ||
Primary education | 131 | 26 (19%) | 0.63 (0.38-1.04) | 0.07 | 0.66 (0.39-1.07) | 0.06 |
Secondary education | 30 | 7 (5%) | 0.77 (0.32-1.87) | 0.57 | 0.74 (0.31-1.79) | 0.61 |
Post-secondary / Tertiary / Advanced education (M.Sc, PhD) | 147 | 25 (18%) | 0.53 (0.32-0.88) | 0.01 | 0.60 (0.30-0.86) | 0.02 |
Socio-economic class
| ||||||
Class 1 | 23 | 6 (4%) | Ref | |||
Class 2 | 93 | 18 (13%) | 0.68 (0.23-1.97) | 0.48 | ||
Class 3 | 260 | 55 (40%) | 0.76 (0.29-2.02) | 0.58 | ||
Class 4 | 195 | 55 (40%) | 1.11 (0.42-2.97) | 0.83 | ||
Class 5 | 20 | 4 (3%) | 0.71 (0.17-2.98) | 0.64 | ||
Current smoker
| ||||||
Yes | 10 | 3 (2%) | 1.42 (0.36-5.55) | 0.62 | ||
No | 581 | 135 (98%) | Ref | |||
Current drug user
| ||||||
Yes | 1 | 0 (0%) | Omitted | Omitted | ||
No | 590 | 138 (100%) | Ref | |||
Current alcohol user
| ||||||
Yes | 47 | 14 (10%) | 1.44 (0.75-2.77) | 0.28 | ||
No | 544 | 124 (90%) | Ref | |||
Current herbal drug user
| ||||||
Yes | 17 | 6 (4%) | 1.83 (0.66-5.03) | 0.24 | ||
No | 574 | 132 (96%) | Ref |
Characteristics | ||||||
---|---|---|---|---|---|---|
ALL | Immunologic failure | Unadjusted | p-value | Adjusted | p-value | |
(n = 596) | (n = 135) | OR (95% CI) | OR (95% CI) | |||
Gender
| ||||||
Female | 377 | 84 (62%) | Ref | Ref | ||
Male | 219 | 51 (38%) | 1.06 (0.71-1.57) | 0.78 | 1.46 (1.04-2.45) |
0.04
|
Age at HAART Initiation
(years)
| ||||||
< 30 | 178 | 42 (31%) | 1.55 (1.01-2.37) | 0.04 | 1.50 (1.11-2.39) |
0.03
|
>30 | 357 | 93 (69%) | Ref | Ref | ||
Currently married
| ||||||
Yes | 336 | 76 (56%) | 0.99 (0.68-1.47) | 0.98 | ||
No | 260 | 59 (44%) | Ref | |||
Residential Distance
(in kilometers)
| ||||||
< 50 | 376 | 92 (68%) | Ref | Ref | ||
51 to100 | 78 | 19 (14%) | 0.99 (0.56-1.75) | 0.98 | 1.19 (0.64-2.33) |
0.79
|
>100 | 142 | 24 (18%) | 0.63 (0.38-1.03) | 0.07 | 0.68 (0.40-1.21) |
0.32
|
HIV disclosure
| ||||||
Yes | 564 | 129 (22.9%) | 0.78 (0.31-1.93) | 0.59 | ||
No | 32 | 6 (18.8%) | Ref | |||
Tuberculosis History
| ||||||
Yes | 85 | 14 (29.6%) | 0.64 (0.35-1.17) | 0.14 | 0.66 (0.40-1.36) |
0.27
|
No | 511 | 121 (70.4%) | Ref | Ref | ||
Baseline anemia
(Hemoglobin <
10 g/dl)
(n = 546)
| ||||||
Yes | 186 | 40 (20.4%) | 1.26 (0.83-1.92) | 0.27 | 1.05 (0.65-1.61) |
0.75
|
No | 410 | 95 (23.7%) | Ref | Ref | ||
Antiretroviral drug regimen at baseline
| ||||||
ZDV / 3TC / NVP or EFV | 242 | 58 (43%) | Ref | |||
D4T / 3TC / NVP or EFV | 47 | 13 (9.6%) | 1.21(0.59-2.45) | 0.59 | 1.61 (0.69-3.53) |
0.29
|
TDT / 3TC or FTC / NVP or EFV | 307 | 64 (47.4%) | 0.84 (0.56-1.25) | 0.38 | 1.14 (0.77-1.53) |
0.83
|
Drug adherence by pharmacy refill record
| ||||||
>= 95% | 549 | 122 (90.4%) | Ref | Ref | ||
< 95% | 47 | 13 (9.6%) | 1.34 (0.68-2.61) | 0.39 | 1.42 (0.71-2.86) |
0.28
|
Employment status
| ||||||
Employed | 496 | 110 (81.5%) | Ref | |||
Unemployed | 95 | 25 (18.5%) | 1.25 (0.76-2.07) | 0.38 | ||
Retired | 1 | 0 (0%) | Omitted | Omitted | ||
Student | 4 | 0 (0%) | Omitted | Omitted | ||
Highest educational achievement
| ||||||
No formal education | 288 | 64 (47.4%) | Ref | |||
Primary education | 134 | 28 (20.7%) | 0.92 (0.56-1.53) | 0.76 | ||
Secondary education | 32 | 10 (7.4%) | 1.59 (0.72-3.53) | 0.25 | ||
Post-secondary / Tertiary / Advanced education (M.Sc., Ph.D.) | 142 | 33 (24.4%) | 1.09 (0.67-1.76) | 0.73 | ||
Socio-economic class
| ||||||
Class 1 | 22 | 4 (3%) | Ref | |||
Class 2 | 91 | 17 (12.6%) | 1.03 (0.31-3.45) | 0.96 | ||
Class 3 | 262 | 68 (50.4%) | 1.58 (0.52-4.82) | 0.42 | ||
Class 4 | 199 | 42 (31%) | 1.20 (0.39-3.75) | 0.75 | ||
Class 5 | 22 | 4 (3%) | 1.00 (0.22-4.63) | 1.00 | ||
Current smoker
| ||||||
Yes | 11 | 4 (97%) | 1.98 (0.57-6.87) | 0.28 | ||
No | 585 | 131 (3%) | Ref | |||
Current drug user
| ||||||
Yes | 0 | 0(0%) | Omitted | Omitted | ||
No | 596 | 135 (100%) | Ref | |||
Current alcohol user
| ||||||
Yes | 50 | 8 (6%) | 0.63 (0.29-1.37) | 0.24 | ||
No | 546 | 127 (94%) | Ref | |||
Current herbal drug user
| ||||||
Yes | 17 | 6 (4%) | 1.90 (0.69-5.24) | 0.21 | ||
No | 579 | 129 (96%) | Ref |
Predictors of Immuno-virologic discordance at 12 months on ART
Characteristics | ||||||
---|---|---|---|---|---|---|
Immuno-virologic success (VL <400 copies and CD4 change >=50 cells) | Virologic discordance (VL >400 copies and CD4 change >=50 cells) | Unadjusted | p-value | Adjusted | p-value | |
(n = 338) | (n = 94) | OR (95% CI) | OR (95% CI) | |||
Gender
| ||||||
Female | 214 (63%) | 58 (62%) | Ref | Ref | ||
Male | 124 (37%) | 36 (38%) | 1.07 (0.67-1.72) | 0.78 | 1.25 (0.72-2.01) | 0.54 |
Age at HAART Initiation
(years)
| ||||||
< 30 | 269 (80%) | 66 (70%) | 1.65 (0.99-2.77) | 0.06 | 1.58 (0.88-3.01) | 0.08 |
>30 | 69 (20%) | 28 (30%) | Ref | Ref | ||
Currently married
| ||||||
Yes | 188 (56%) | 57 (61%) | 1.23 (0.77-1.96) | 0.39 | ||
No | 150 (44%) | 37 (39%) | Ref | |||
HIV disclosure
| ||||||
Yes | 317 (93.8%) | 89 (95%) | 1.18 (0.43-3.22) | 0.75 | ||
No | 21 (6.2%) | 5 (5%) | Ref | |||
Tuberculosis History
| ||||||
Yes | 49 (14.5%) | 17 (18.1%) | 1.30 (0.71-2.39) | 0.39 | 0.92 (0.47-1.86) | 0.92 |
No | 289 (85.5%) | 77 (81.9%) | Ref | Ref | ||
Baseline CD4 cell count
(n = 613)
| ||||||
< 50 | 57 (16.9%) | 19 (20.2%) | Ref | Ref | ||
50 and < 200 | 196 (58%) | 59 (62.8%) | 0.90 (0.50-1.64) | 0.74 | 0.90 (0.56-1.61) | 0.81 |
200 and <350 | 72 (21.3%) | 13 (13.8%) | 0.54 (0.25-1.19) | 0.13 | 0.59 (0.20-1.38) | 0.22 |
350 and < 500 | 9 (2.7%) | 3 (3.2%) | 1.00 (0.25-4.08) | 1.0 | 0.58 (0.16-3.22) | 0.65 |
>=500 | 4 (1.1%) | 0 (0%) | Omitted | |||
Baseline anemia
(Hemoglobin <
10 g/dl)
(n = 546)
| ||||||
Yes | 103 (30.5%) | 40 (42.5%) | 1.69 (1.05-2.70) | 0.03 | 1.80 (1.13-2.85) | 0.04 |
No | 235 (69.5%) | 54 (57.5%) | Ref | Ref | ||
Antiretroviral drug regimen at baseline
| ||||||
ZDV / 3TC / NVP or EFV | 139 (41%) | 37 (39%) | Ref | Ref | ||
D4T / 3TC / NVP or EFV | 24 (7%) | 9 (10%) | 1.41 (0.60-3.29) | 0.43 | 1.21 (0.42-3.95) | 0.59 |
TDF / 3TC of FTC / NVP or EFV | 175 (52%) | 48 (51%) | 1.03 (0.64-1.67) | 0.90 | 0.89 (0.46-1.43) | 0.86 |
Drug adherence by pharmacy refill record
| ||||||
>= 95% | 322 (95%) | 79 (84%) | Ref | Ref | ||
< 95% | 16 (5%) | 15 (16%) | 3.82 (1.81-8.06) | 0.001 | 3.90 (1.92-8.24) | 0.001 |
Employment status
| ||||||
Employed | 288 (85.2%) | 75 (79.8%) | Ref | Ref | ||
Unemployed | 46 (13.6%) | 18 (19.1%) | 1.50 (0.82-2.74) | 0.18 | 1.44 (0.77-2.56) | 0.31 |
Retired | 1 (0.3%) | 0 (0%) | Omitted | Omitted | Omitted | |
Student | 3 (0.9%) | 1 (1.1%) | 1.28 (0.13-12.5) | 0.83 | 1.33 (0.15-11.7) | 0.87 |
Highest educational achievement
| ||||||
No formal education | 152 (45%) | 58 (61.7%) | Ref | Ref | ||
Primary education | 84 (24.9%) | 18 (19.2%) | 0.56 (0.31-1.02) | 0.06 | 0.56 (0.29-1.01) | 0.06 |
Secondary education | 14 (4.1%) | 5 (5.3%) | 0.94 (0.32-2.72) | 0.90 | 0.92 (0.27-2.49) | 0.72 |
Post-secondary / Tertiary / Advanced education | 88 (26%) | 13 (13.8%) | 0.40 (0.21-0.77) | 0.006 | 0.40 (0.22-0.68) | 0.004 |
Socio-economic class
| ||||||
Class 1 | 14 (4.1%) | 4 (4.3%) | Ref | |||
Class 2 | 54 (16%) | 14 (14.9%) | 0.91 (0.26-3.19) | 0.88 | ||
Class 3 | 147 (43.5%) | 33 (35.1%) | 0.79 (0.24-2.54) | 0.69 | ||
Class 4 | 110 (32.5%) | 41 (43.6%) | 1.30 (0.41-.4.19) | 0.66 | ||
Class 5 | 13 (3.9%) | 2 (2.1%) | 0.54 (0.08-3.45) | 0.51 | ||
Current smoker
| ||||||
Yes | 5 (1.5%) | 1 (98.9%) | 0.72 (0.08-6.21) | 0.76 | ||
No | 333 (98.5%) | 93 (1.1%) | Ref | |||
Current alcohol user
| ||||||
Yes | 28 (8.3%) | 8 (8.5%) | 1.03 (0.45-2.34) | 0.94 | ||
No | 310 (91.7%) | 86 (91.5%) | Ref | |||
Current herbal drug user
| ||||||
Yes | 7 (2.1%) | 3 (3.2%) | 1.56 (0.39-6.15) | 0.53 | ||
No | 331 (97.9%) | 91 (96.8%) | Ref |
Characteristics | ||||||
---|---|---|---|---|---|---|
Immuno-virologic success (VL <400 copies and CD4 change >=50 cells) | Immunologic discordance (VL <400 copies and CD4 change <50 cells) | Unadjusted | p-value | Adjusted | p-value | |
(n = 338) | (n = 90) | OR (95% CI) | OR (95% CI) | |||
Gender
| ||||||
Female | 214 (63%) | 55 (61.1%) | Ref | Ref | ||
Male | 124 (37%) | 35 (38.9%) | 1.09 (0.68-1.77) | 0.90 | 1.88 (1.05-3.11) | 0.04 |
Age at HAART Initiation
(years)
| ||||||
< 30 | 269 (80%) | 27 (30%) | 1.67 (0.99-2.82) | 0.05 | 1.76 (0.91-3.20) | 0.08 |
>30 | 69 (20%) | 63 (70%) | Ref | Ref | ||
Currently married
| ||||||
Yes | 188 (56%) | 54 (60%) | 1.19 (0.75-1.92) | 0.46 | ||
No | 150 (44%) | 36 (40%) | Ref | |||
HIV disclosure
| ||||||
Yes | 317 (93.8%) | 86 (95.6%) | 1.42 (0.48-4.26) | 0.53 | ||
No | 21 (6.2%) | 4 (4.4%) | Ref | |||
Tuberculosis History
| ||||||
Yes | 49 (14.5%) | 5 (5.6%) | 0.35 (0.13-0.90) | 0.03 | 0.43 (0.21-1.09) | 0.08 |
No | 289 (85.5%) | 85 (94.4%) | Ref | Ref | ||
Baseline CD4 cell count
(n = 613)
| ||||||
< 50 | 57 (16.9%) | 3 (3.3%) | Ref | Ref | ||
50 and < 200 | 196 (58%) | 35 (38.9%) | 3.39 (1.01-11.44) | 0.049 | 3.17 (0.93-10.86) | 0.07 |
200 and <350 | 72 (21.3%) | 42 (46.7%) | 11.08 (3.27-37.61) | 0.001 | 9.90 (2.79-35.10) | >0.001 |
350 and < 500 | 9 (2.7%) | 6 (6.7%) | 12.67 (2.68-59.92 | 0.001 | 13.5 (2.59-70.13) | 0.002 |
>=500 | 4 (1.1%) | 4 (4.4%) | 18.99 (3.12-115.86 | 0.001 | 19.1 (2.91-125.59) | 0.002 |
Baseline anemia
(Hemoglobin <
10 g/dl)
(n = 546)
| ||||||
Yes | 103 (30.5%) | 24 (26.7%) | 1.21 (0.72-2.03) | 0.48 | 1.04 (0.55-1.88) | 0.94 |
No | 235 (69.5%) | 66 (73.3%) | Ref | Ref | ||
Antiretroviral drug regimen at baseline
| ||||||
ZDV / 3TC / NVP or EFV | 139 (41%) | 39 (43.3%) | Ref | Ref | ||
D4T / 3TC / NVP or EFV | 24 (7%) | 8 (8.9%) | 1.18 (0.49-2.85) | 0.70 | 1.74 (0.64-4.76) | 0.25 |
TDF / 3TC of FTC / NVP or EFV | 175 (52%) | 43 (47.8%) | 0.88 (0.54-1.43) | 0.59 | 1.29 (0.72-2.22) | 0.43 |
Drug adherence by pharmacy refill record
| ||||||
>= 95% | 322 (95%) | 85 (94.4%) | Ref | Ref | ||
< 95% | 16 (5%) | 5 (5.6%) | 1.18 (0.43-3.22) | 0.75 | 1.20 (0.41-2.91) | 0.64 |
Employment status
| ||||||
Employed | 288 (85.2%) | 74 (82.2%) | Ref | |||
Unemployed | 46 (13.6%) | 16 (17.8%) | 1.35 (0.73-2.53) | 0.34 | ||
Retired | 1 (0.3%) | 0 (0%) | Omitted | |||
Student | 3 (0.9%) | 0 (0%) | Omitted | |||
Highest educational achievement
| ||||||
No formal education | 152 (45%) | 41 (45.6%) | Ref | Ref | ||
Primary education | 84 (24.9%) | 20 (22.2%) | 0.88 (0.49-1.60) | 0.68 | ||
Secondary education | 14 (4.1%) | 7 (7.8%) | 1.85 (0.70-4.89) | 0.21 | ||
Post-secondary / Tertiary / Advanced education | 88 (26%) | 22 (24.4%) | 0.96 (0.54-1.72) | 0.89 | ||
Socio-economic class
| ||||||
Class 1 | 14 (4.1%) | 2 (2.2%) | Ref | |||
Class 2 | 54 (16%) | 13 (14.5%) | 1.69 (0.34-8.35) | 0.52 | ||
Class 3 | 147 (43.5%) | 48 (53.3%) | 2.29 (0.50-10.40) | 0.29 | ||
Class 4 | 110 (32.5%) | 25 (27.8%) | 1.59 (0.34-7.45) | 0.56 | ||
Class 5 | 13 (3.9%) | 2 (2.2%) | 1.08 (0.13-8.79) | 0.95 | ||
Current smoker
| ||||||
Yes | 5 (1.5%) | 2 (2.2%) | 1.51 (0.29-7.93) | 0.62 | ||
No | 333 (98.5%) | 88 (97.8%) | Ref | |||
Current alcohol user
| ||||||
Yes | 28 (8.3%) | 3 (3.3%) | 0.38 (0.11-1.29) | 0.12 | 0.28 (0.09-1.27) | 0.09 |
No | 310 (91.7%) | 87 (96.7%) | Ref | Ref | ||
Current herbal drug user
| ||||||
Yes | 7 (2.1%) | 3 (3.3%) | 1.63 (0.41-6.44) | 0.49 | ||
No | 331 (97.9%) | 87 (96.7%) | Ref |